



CASE 4-309

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10				
EL 239201335 US Express Mail Label Number	February 19, 2002 Date of Deposit			J
IN THE UNITED STATES PATENT AND TR	RADEMARK OFFICE	MAR 1 3		ECE
E PCT NATIONAL STAGE APPLICATION OF NOUD ET AL.		1600/2900	2002	VED.

IN RE CUEN

INTERNATIONAL APPLICATION NO: PCT/EP00/05058

FILED: 2 JUNE 2000

U.S. APPLICATION NO: 10/009,008

35 USC §371 DATE: 8 JANUARY 2002

FOR: BETA2-ADRENOCEPTOR AGONISTS

Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

References AK to AP were cited in the International Stage Search report, a copy of which is enclosed. Since these references are of record in the instant PCT/EP00/05058 application, copies are not enclosed herewith.

Enclosed is reference EP 0286 278 A1 and an Abstract of WO93/18007 A1, which were cited in an UK Search Report in a corresponding application. These references and the search report are enclosed. In addition Applicants are enclosing the South African reference ZA 987425,

which is substantially equivalent to reference AM (WO 93 1007A.) listed in the International Search Report.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis Corporation Patent and Trademark Dept. 564 Morris Avenue Summit, NJ 07901-1027 (908) 522-6932

Date: February 19, 2002

Respectfully submitted,

Carol A. Loeschorn Attorney for Applicants Reg. No. 35,590